What is the generic for lipitor
Pro Research Analysisby 
Searched over 200M research papers
Generic for Lipitor: Atorvastatin
Introduction to Lipitor and Its Generic Version
Lipitor, known generically as atorvastatin, is one of the most widely prescribed medications for lowering cholesterol. It belongs to a class of drugs called statins, which work by reducing levels of low-density lipoprotein (LDL) cholesterol in the blood, thereby decreasing the risk of cardiovascular events such as heart attacks and strokes .
Bioequivalence and Clinical Effectiveness of Generic Atorvastatin
Generic medications are approved based on their bioequivalence to brand-name drugs, meaning they must demonstrate that they deliver the same amount of active ingredients into a patient's bloodstream in the same amount of time as the original drug. Despite this, there has been ongoing concern about the clinical effectiveness and safety of generic drugs compared to their brand-name counterparts .
A comprehensive study conducted in Ontario, Canada, compared the effectiveness of generic atorvastatin with Lipitor in patients aged 65 and older who were discharged after hospitalization for acute coronary syndrome (ACS). The study found no significant difference in the primary outcome of death or recurrent ACS hospitalization at one year between patients prescribed generic atorvastatin and those prescribed Lipitor. Additionally, there were no significant differences in secondary outcomes such as hospitalization for heart failure, stroke, new-onset diabetes, rhabdomyolysis, and renal failure .
Economic Impact of Generic Atorvastatin
The introduction of generic atorvastatin has had a significant economic impact. Lipitor was the top-selling prescription drug in the United States until its patent expired in June 2011. The availability of generic atorvastatin, which entered the market in November 2011, has led to substantial cost savings for both patients and healthcare systems .
Despite the availability of generic atorvastatin, some healthcare plans and pharmacy benefit managers have continued to promote the use of branded Lipitor through various programs. These programs aimed to maintain patient access to Lipitor at a cost comparable to or lower than that of the generic version during the initial 180-day period following the loss of market exclusivity.
Regulatory and Legal Challenges
The approval process for generic drugs involves obtaining an abbreviated new drug application (ANDA) from the FDA. The first company to receive ANDA approval is granted 180 days of market exclusivity. Ranbaxy was the first to receive approval for generic atorvastatin, but faced significant regulatory challenges due to manufacturing issues, which delayed the market entry of other generic versions .
Conclusion
In summary, atorvastatin is the generic version of Lipitor and has been shown to be equally effective and safe in clinical settings. The introduction of generic atorvastatin has led to significant cost savings and increased accessibility for patients. Despite initial regulatory and legal challenges, the availability of generic atorvastatin has provided a valuable alternative to the brand-name drug without compromising clinical outcomes.
Sources and full results
Most relevant research papers on this topic